Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
03. Februar 2022 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
11. Januar 2022 14:15 ET
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers First Patient Dosed in Global Phase...
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
04. Januar 2022 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted...
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
24. November 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
10. November 2021 16:05 ET
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company...
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
08. November 2021 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
03. November 2021 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
30. September 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
15. September 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07. September 2021 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...